Figure 3.

(A) Progression-free survival (PFS) to first-line molecular targeted therapy (MTT) stratified by MTTagent (everolimus vs sunitinib) with patient at risk table below. (B) Progression-free survival (PFS) to second-line molecular targeted therapy (MTT) stratified by MTT agent (everolimus vs sunitinib) with patient at risk table below.